Lavipharm S.A.

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E. Other stock markets 07:43:03 31/05/2024 pm IST			5-day change	1st Jan Change
0.917 ^EUR	-0.76%		-4.88%	+15.20%

28/02	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	CI

Lavipharm S A : ANNOUNCEMENT

March 28, 2023 at 08:19 pm IST

ANNOUNCEMENT

Paiania, 28 March 2023 - Lavipharm S.A., according to the provisions of article 19 of the European Regulation No 596/2014 and the Regulation of the Athens Exchange, announces the appointment of Mr. Evangelos Paterakis as Chief Accountant replacing Mr. Panagiotis Pavlou, who is retiring.

ANNOUNCEMENT

Attachments

Original Link
Original Document
Permalink

Disclaimer

Lavipharm SA published this content on 28 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 March 2023 14:48:10 UTC.

Latest news about Lavipharm S.A.

Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	11/12	CI
Lavipharm S.A. signing of an asset purchase agreement to acquire Lonarid N and Lonalgal from Boehringer Ingelheim International GmbH.	01/12	CI
Lavipharm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	08/11	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21	CI
Lavipharm S.A.(ATSE:LAVI) added to ATHEX Composite Index	21/23/21	CI
Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/23/04	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	15/22/15	CI
Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	21/22/21	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	21/22/21	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	29/21/29	CI
Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	26/21/26	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	26/21/26	CI
Zentiva Reinforces Its Presence in Greece by Signing A Partnership with the Company Lavipharm S.A	19/20/19	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	08/20/08	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	25/19/25	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	27/18/27	CI
Lavipharm Announces Consolidated Earnings Results for the First Half of 2015	21/15/21	CI
Robertet SA and Codif Recherche & Nature acquired Hitex S.A. from Lavipharm S.A. for €3.1 million.	01/14/01	CI
Lavipharm S.A. Announces Earnings Results for the Year Ended December 31, 2011	25/12/25	CI
Lavipharm S.A. Reports Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	30/12/30	CI
Lavipharm SA Reports Consolidated and Company Earnings Results for the First Quarter Ended March 31, 2012	30/12/30	CI

Chart Lavipharm S.A.

Duration

Period

More charts

Company Profile

Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
LAVIPHARM S.A.	+15.20%	168M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	42.02B
OTSUKA HOLDINGS CO., LTD.	+22.40%	21.66B
SANDOZ GROUP AG	+18.48%	15.09B
CIPLA LIMITED	+16.12%	14.21B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.37B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.59B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.56B